News Column

arGEN-X Partners with Bayer to Investigate Therapeutic Antibody Candidates

June 2, 2014

arGEN-X said it began a collaboration with Bayer Pharma, leveraging arGEN-X's SIMPLE Antibody technology for the discovery and development of therapeutic antibodies.

According to a company release, the collaboration centers on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms.

"We are delighted that Bayer, with its long-standing expertise in drug development, will make use of the SIMPLE Antibody platform. As a company, we are dedicated to forming elite partnerships and feel that with this new collaboration, we have firmly established SIMPLE Antibody as an innovative solution to reaching intractable targets and tackling unmet needs in antibody discovery," said Tim Van Hauwermeiren, Chief Executive Officer of arGEN-X. "We are confident that by building on our proprietary capabilities in DNA immunization and the unique immune system of the llama, we have developed a novel platform that will create potential new product opportunities."

"We look forward to collaborating with arGEN-X and exploring the potential of SIMPLE Antibody technology to complement Bayer's efforts in the discovery and development of first-in-class therapeutic antibodies," said Dr. Harald Dinter, Head of Global Biologics at Bayer Pharma AG.

arGEN-X is a clinical-stage biopharmaceutical company.

More information and complete details:

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Health & Beauty Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters